VA data shows 2024-2025 COVID shots still protect seniors’ heart outcomes

Most Americans may have skipped seasonal COVID-19 vaccines, but for cardiovascular risk, the updated shots still matter. A new study, published in JAMA Internal Medicine, pulled data from more than 1 million patients in a US Department of Veterans Affairs (VA) health system and found that the 2024-2025 COVID-19 vaccine continued to protect against COVID-19-associated major adverse cardiovascular events, or MACE.

MACE is not an abstract endpoint. In the study, it included cardiovascular death, heart attack, stroke, and hospitalization for heart failure. The analysis also points to who benefits most clearly: people over age 75 and those with underlying medical conditions. That matters because these are the groups where health systems and payers feel the bill first and hardest, even if overall uptake is lower.

This is also the kind of finding that gets scrutinized for staying power. The study explicitly notes that it was not guaranteed the benefit would hold up over time. The reasons are built into how COVID plays out: the virus evolved, vaccines were updated, population-level immunity increased from previous infection and vaccination, and the risk of severe outcomes fell. In other words, you could have had a world where the vaccines stopped translating into measurable heart protection, especially as baseline risk changed.

Instead, the study adds evidence that the updated vaccine still reduces COVID-linked cardiovascular harms, especially for heart attacks and strokes. That aligns with previous data the article says had already shown vaccines significantly lower the risk of COVID-19-associated cardiovascular risks. This new analysis is important because it extends the story from “vaccines help” to “vaccines help even as conditions shift.” For health executives, investors in healthcare services, and board members tracking population health outcomes, that is the difference between one-time relief and durable value.

Now zoom out to the demand side, because the source also flags the uncomfortable reality: anti-vaccine rhetoric has driven down vaccination. That means the clinical benefit exists, but behavior does not automatically follow evidence. In a typical healthcare system, uptake affects throughput, and throughput affects costs, staffing, and downstream utilization like cardiology and hospital admissions. Even if the updated shots continue to protect, lower vaccination rates can mean health systems still carry avoidable cardiovascular events tied to COVID.

Regulatory and market context makes this even more consequential. Seasonal COVID-19 vaccines are iterated, and the point of updating is to maintain relevance as the virus changes. Here, the study’s message is that this update cycle is not just regulatory housekeeping. It is producing measurable protection against serious cardiovascular outcomes in a real-world setting, not only in controlled trials. The data comes from a VA health system, which is a reminder that outcomes research at scale has different strengths than research rooted in voluntary, highly selected cohorts.

There is a second-order implication for organizations that manage risk at population level: when severe COVID risk falls overall, it can mask the distribution of harm. The fact that protection persists for older adults and those with underlying conditions suggests a targeting problem for strategy, not a disappearance of value. If you only look at aggregate metrics, you might conclude the urgency has faded. If you look at subgroup outcomes, the signal stays sharp.

The strategic stakes for executives are simple and non-negotiable. Health plans, hospital systems, and any leadership team making resource allocation decisions need to understand whether cardiovascular protection from updated vaccination is real and continuing. This study, based on data from more than 1 million VA patients, says yes for the 2024-2025 vaccine against COVID-associated MACE. Even if not everyone gets the shot, the organizations that plan for higher-risk patients, advocate for prevention, and track downstream events will be the ones best positioned when COVID surges or circulates enough to stress the cardiovascular pipeline.